Select Page

Type I Diabetes

Below is a sample of existing clinical evidence:

“Twenty-nine patients with newly onset T1DM were randomly divided into two groups, patients in group I were treated with (intravenous) WJ-MSCs (Wharton’s Jelly Mesenchymal Stem Cells) and patients in group II were treated with normal saline based on insulin intensive therapy… There were no reported acute or chronic side effects in group I compared with group II, both the HbA1c and C peptide in group I patients were significantly better than either pretherapy values or group II patients.”

– “Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus,” Hu et al, Endocrine Journal Advanced Publication, 2012

Contact Us to Receive a Quote

Pin It on Pinterest

Share This